Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 22, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 650,000 ordinary shares of 25 pence each.
- Purchase Price: 1,409.77 pence per share.
- Treasury Holdings: Following the purchase, the company holds 243,732,678 shares in Treasury.
- Shares in Issue: 5,751,658,288 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 650,000 shares on January 22, 2007. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,751,658,288) for calculating voting rights and disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count of 243,732,678 following the January 22, 2007 transaction.
- Note that this filing is a regulatory disclosure of a share buyback and does not contain quarterly or annual financial performance results.